文献速递眼底病与葡萄膜炎

新生血管性眼病抗VEGF治疗获得性耐药机制

Mechanisms of Acquired Resistance to Anti-VEGF Therapy for Neovascular Eye Diseases.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2023-01-01

本综述分析新生血管性年龄相关性黄斑变性(AMD)和糖尿病黄斑水肿(DME)患者反复抗VEGF治疗后反应丧失的临床报告与实验证据。作者提出切换至替代血管生成通路可能绕过VEGF阻断,以及眼部内皮糖酵解代谢重编程可能损害血视网膜屏障功能,两者共同参与获得性耐药。

要点

  • 抗VEGF生物制剂是新生血管性AMD和DME的一线治疗,但部分患者反复给药后渗出复发。
  • 作者假设切换至替代血管生成通路可能绕过VEGF阻断,导致抗VEGF治疗耐药。
  • 作者提出VEGF拮抗后眼部内皮糖酵解重编程可能损害血视网膜屏障功能,削弱疗效。

核心结论

  • 未来针对本综述所提出机制的研究可能揭示这些适应性改变如何导致抗VEGF治疗获得性耐药,有助于发现克服耐药的新策略并提高临床疗效。

研究设计与样本

  • 综述已发表的临床研究和实验研究。

主要发现

  • 玻璃体腔注射抗VEGF生物制剂(如贝伐珠单抗、雷珠单抗和阿柏西普)通过阻止过度血管生长和渗漏的进展发挥作用。
  • 尽管临床结果良好,部分患者反复给药后渗出仍会复发,可能已产生获得性抗VEGF治疗耐药。
  • 作者分析VEGF靶向治疗后血管生成信号通路变化的临床与临床前发现,假设切换至替代通路可能绕过VEGF阻断。
  • 作者讨论VEGF拮抗后眼部内皮糖酵解的重编程,提出代谢适应可能损害血视网膜屏障功能并削弱VEGF靶向治疗的临床疗效。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The purpose of this study was to evaluate clinical reports of response-loss in patients with neovascular eye diseases, such as neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME), after repeated anti-vascular endothelial growth factor (VEGF) therapy. To assess experimental evidence of associations of other angiogenic growth factors and endothelial glycolytic pathways with the diseases and to propose the underlying mechanisms. METHODS: Review of published clinical studies and experimental investigations. RESULTS: Intravitreal injection of anti-VEGF biologic drugs (e.g. bevacizumab, ranibizumab, and aflibercept) is the front-line treatment for neovascular AMD and DME, and acts by halting the progression of excess blood vessel growth and leakage. Despite favorable clinical results, exudation returns in a number of patients after repeated administrations over time. Patients suffering from disease recurrence may have developed an acquired resistance to anti-VEGF therapy. We have analyzed clinical and preclinical findings on changes to angiogenic signaling pathways following VEGF-targeted treatment and hypothesize that switching to alternative pathways could potentially bypass VEGF blockade, accounting for development of resistance to anti-VEGF therapy. We have also discussed potential reprogramming of ocular endothelial glycolysis in response to VEGF antagonism and proposed that metabolic adaptations could impair blood-retinal barrier function, counteracting the clinical efficacy of VEGF-targeted therapies and contributing to a decline of response to them. CONCLUSIONS: Future studies of the mechanisms proposed in this review may shed some light on how these adaptations result in the development of acquired resistance to anti-VEGF therapy, which should help discover new therapeutic strategies for overcoming anti-VEGF resistance and improving clinical efficacy.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Sharma D, Zachary I, Jia H, et al. Mechanisms of Acquired Resistance to Anti-VEGF Therapy for Neovascular Eye Diseases. Invest Ophthalmol Vis Sci. 2023. PMID: 37252731. doi:10.1167/iovs.64.5.28

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。